S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in

Marinus Pharmaceuticals Stock Forecast, Price & News

+0.93 (+6.69 %)
(As of 02/24/2021 12:00 AM ET)
Today's Range
Now: $14.84
50-Day Range
MA: $13.50
52-Week Range
Now: $14.84
Volume184,241 shs
Average Volume322,156 shs
Market Capitalization$454.01 million
P/E RatioN/A
Dividend YieldN/A
Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors and exhibits anti seizure, antidepressant, and anxiolytic actions through its effects on. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment resistant depression. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Marinus Pharmaceuticals logo


Stock Alert: Marinus Pharmaceuticals Climbs 11%
January 13, 2021 |  nasdaq.com
MRNS Jan 2021 10.000 put
December 23, 2020 |  uk.finance.yahoo.com
MRNS Apr 2021 12.000 call
December 22, 2020 |  uk.finance.yahoo.com
MRNS Apr 2021 11.000 put
December 21, 2020 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MRNS
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$2.90 per share


Net Income$-54,120,000.00


Market Cap$454.01 million
Next Earnings Date3/9/2021 (Confirmed)


Overall MarketRank

1.72 out of 5 stars

Medical Sector

189th out of 1,958 stocks

Pharmaceutical Preparations Industry

86th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.93 (+6.69 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

Is Marinus Pharmaceuticals a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Marinus Pharmaceuticals stock.
View analyst ratings for Marinus Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Marinus Pharmaceuticals?

Wall Street analysts have given Marinus Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Marinus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Marinus Pharmaceuticals?

Marinus Pharmaceuticals saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 4,350,000 shares, a decline of 17.6% from the December 31st total of 5,280,000 shares. Based on an average daily trading volume, of 534,100 shares, the short-interest ratio is presently 8.1 days. Approximately 13.3% of the company's shares are sold short.
View Marinus Pharmaceuticals' Short Interest

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Marinus Pharmaceuticals

How can I listen to Marinus Pharmaceuticals' earnings call?

Marinus Pharmaceuticals will be holding an earnings conference call on Tuesday, March 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) posted its earnings results on Monday, November, 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.09.
View Marinus Pharmaceuticals' earnings history

How has Marinus Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Marinus Pharmaceuticals' stock was trading at $6.56 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MRNS stock has increased by 126.2% and is now trading at $14.84.
View which stocks have been most impacted by COVID-19

When did Marinus Pharmaceuticals' stock split? How did Marinus Pharmaceuticals' stock split work?

Marinus Pharmaceuticals shares reverse split on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of Marinus Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for MRNS?

10 equities research analysts have issued twelve-month price targets for Marinus Pharmaceuticals' stock. Their forecasts range from $18.00 to $35.00. On average, they anticipate Marinus Pharmaceuticals' stock price to reach $27.22 in the next year. This suggests a possible upside of 83.4% from the stock's current price.
View analysts' price targets for Marinus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the following people:
  • Dr. Scott Braunstein, CEO & Pres (Age 58, Pay $562.48k)
  • Mr. Edward F. Smith CPA, VP, CFO, Treasurer (Age 50, Pay $550.75k)
  • Dr. Joseph Hulihan M.D., Chief Medical Officer (Age 65, Pay $342.3k)
  • Ms. Sasha Damouni Ellis, VP of Investor Relations & Corp. Communication
  • Ms. Martha E. Manning, VP, Gen. Counsel & Sec. (Age 66)
  • Mr. Thomas J. Lyons, VP of Corp., Bus. Devel. & Commercial Planning
  • Ms. Rose McKinley, VP of HR & Organizational Devel.
  • Dr. Alex Aimetti, Head of Scientific Affairs
  • Ms. Christy Shafer, Chief Commercial Officer
  • Mr. Henrikas Vaitkevicius M.D., VP of Clinical Devel.

Who are some of Marinus Pharmaceuticals' key competitors?

What other stocks do shareholders of Marinus Pharmaceuticals own?

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Lion Point Capital LP (11.83%), Avoro Capital Advisors LLC (10.56%), BlackRock Inc. (6.80%), Alyeska Investment Group L.P. (4.07%), Alyeska Investment Group L.P. (4.07%) and Bleichroeder LP (2.33%). Company insiders that own Marinus Pharmaceuticals stock include Edward F Smith and Scott Braunstein.
View institutional ownership trends for Marinus Pharmaceuticals

Which major investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Victory Capital Management Inc., Virtus ETF Advisers LLC, Nuveen Asset Management LLC, State of Wisconsin Investment Board, and First Trust Advisors LP.
View insider buying and selling activity for Marinus Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Marinus Pharmaceuticals stock?

MRNS stock was purchased by a variety of institutional investors in the last quarter, including Lion Point Capital LP, Luminus Management LLC, BlackRock Inc., Alyeska Investment Group L.P., Alyeska Investment Group L.P., Artal Group S.A., Avoro Capital Advisors LLC, and Kestra Private Wealth Services LLC.
View insider buying and selling activity for Marinus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $14.84.

How much money does Marinus Pharmaceuticals make?

Marinus Pharmaceuticals has a market capitalization of $454.01 million. The biopharmaceutical company earns $-54,120,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis.

How many employees does Marinus Pharmaceuticals have?

Marinus Pharmaceuticals employs 65 workers across the globe.

What is Marinus Pharmaceuticals' official website?

The official website for Marinus Pharmaceuticals is www.marinuspharma.com.

Where are Marinus Pharmaceuticals' headquarters?

Marinus Pharmaceuticals is headquartered at 100 Matsonford Rd Suite 500, Radnor PA, 19087.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]

This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.